NextCure Inc. (NASDAQ: NXTC)
$0.8400
-0.0529 ( -6.29% ) 63.1K
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
Market Data
Open
$0.8400
Previous close
$0.8929
Volume
63.1K
Market cap
$23.88M
Day range
$0.8420 - $0.9240
52 week range
$0.7600 - $2.5700
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Feb 01, 2024 |
4 | Insider transactions | 1 | Feb 01, 2024 |
4 | Insider transactions | 1 | Feb 01, 2024 |
4 | Insider transactions | 1 | Feb 01, 2024 |
4 | Insider transactions | 1 | Feb 01, 2024 |